Eric Rowinsky, MD
Over 30 years of experience in oncology drug development.
CMO, Hummingbird Biotherapeutics, Inc.
Former Head of R&D at Stemline Therapeutics, Inc.
Former EVP and CMO of ImClone Systems (acquired by Eli Lilly).
Former Director of the Institute of Drug Development, San Antonio Texas and Clinical Professor of Medicine, University of Texas, San Antonio
Former Associate Professor of Oncology at the Johns Hopkins University School of Medicine
MD from the Vanderbilt University School of Medicine